作者: Anja J. Gerrits , Emily A. Leven , Andrew L. Frelinger , Sophie L. Brigstocke , Michelle A. Berny-Lang
DOI: 10.1182/BLOOD-2014-09-602573
关键词:
摘要: Because Wiskott-Aldrich syndrome (WAS) and X-linked thrombocytopenia (XLT) patients have microthrombocytopenia, hemorrhage is a major problem. We asked whether eltrombopag, thrombopoietic agent, would increase platelet counts, improve activation, and/or reduce bleeding in WAS/XLT